BACKGROUND: We report the results of a phase I/II, open-label, single-arm clinical trial to evaluate the safety and anti-human immunodeficiency virus type 1 (HIV-1) efficacy of an autologous dendritic cell (DC)-based HIV-1 vaccine loaded with autologous HIV-1-infected apoptotic cells. METHODS: Antiretroviral therapy (ART)-naive individuals were enrolled, and viremia was suppressed by ART prior to delivery of 4 doses of DC-based vaccine. Participants underwent treatment interruption 6 weeks after the third vaccine dose. The plasma HIV-1 RNA level 12 weeks after treatment interruption was compared to the pre-ART (ie, baseline) level. RESULTS: The vaccine was safe and well tolerated but did not prevent viral rebound during treatment interruption. Vaccination resulted in a modest but significant decrease in plasma viremia from the baseline level (from 4.53 log10 copies/mL to 4.27 log10 copies/mL;P= .05). Four of 10 participants had a >0.70 log10 increase in the HIV-1 RNA load in plasma following vaccination, despite continuous ART. Single-molecule sequencing of HIV-1 RNA in plasma before and after vaccination revealed increases in G>A hypermutants in gag and pol after vaccination, which suggests cytolysis of infected cells. CONCLUSIONS: A therapeutic HIV-1 vaccine based on DCs loaded with apoptotic bodies was safe and induced T-cell activation and cytolysis, including HIV-1-infected cells, in a subset of study participants. CLINICAL TRIALS REGISTRATION: NCT00510497.
BACKGROUND: We report the results of a phase I/II, open-label, single-arm clinical trial to evaluate the safety and anti-human immunodeficiency virus type 1 (HIV-1) efficacy of an autologous dendritic cell (DC)-based HIV-1 vaccine loaded with autologous HIV-1-infected apoptotic cells. METHODS: Antiretroviral therapy (ART)-naive individuals were enrolled, and viremia was suppressed by ART prior to delivery of 4 doses of DC-based vaccine. Participants underwent treatment interruption 6 weeks after the third vaccine dose. The plasma HIV-1 RNA level 12 weeks after treatment interruption was compared to the pre-ART (ie, baseline) level. RESULTS: The vaccine was safe and well tolerated but did not prevent viral rebound during treatment interruption. Vaccination resulted in a modest but significant decrease in plasma viremia from the baseline level (from 4.53 log10 copies/mL to 4.27 log10 copies/mL;P= .05). Four of 10 participants had a >0.70 log10 increase in the HIV-1 RNA load in plasma following vaccination, despite continuous ART. Single-molecule sequencing of HIV-1 RNA in plasma before and after vaccination revealed increases in G>A hypermutants in gag and pol after vaccination, which suggests cytolysis of infected cells. CONCLUSIONS: A therapeutic HIV-1 vaccine based on DCs loaded with apoptotic bodies was safe and induced T-cell activation and cytolysis, including HIV-1-infected cells, in a subset of study participants. CLINICAL TRIALS REGISTRATION: NCT00510497.
Authors: J Banchereau; F Briere; C Caux; J Davoust; S Lebecque; Y J Liu; B Pulendran; K Palucka Journal: Annu Rev Immunol Date: 2000 Impact factor: 28.527
Authors: Bernard J C Macatangay; Marta E Szajnik; Theresa L Whiteside; Sharon A Riddler; Charles R Rinaldo Journal: PLoS One Date: 2010-03-24 Impact factor: 3.240
Authors: Sharon A Riddler; Evgenia Aga; Ronald J Bosch; Barbara Bastow; Margaret Bedison; David Vagratian; Florin Vaida; Joseph J Eron; Rajesh T Gandhi; John W Mellors Journal: J Infect Dis Date: 2015-09-02 Impact factor: 5.226
Authors: Sarah Palmer; Frank Maldarelli; Ann Wiegand; Barry Bernstein; George J Hanna; Scott C Brun; Dale J Kempf; John W Mellors; John M Coffin; Martin S King Journal: Proc Natl Acad Sci U S A Date: 2008-03-10 Impact factor: 11.205
Authors: Sarah Palmer; Ann P Wiegand; Frank Maldarelli; Holly Bazmi; JoAnn M Mican; Michael Polis; Robin L Dewar; Angeline Planta; Shuying Liu; Julia A Metcalf; John W Mellors; John M Coffin Journal: J Clin Microbiol Date: 2003-10 Impact factor: 5.948
Authors: Timothy J Wilkin; John E McKinnon; A Gregory DiRienzo; Katie Mollan; Courtney V Fletcher; David M Margolis; Barbara Bastow; Gary Thal; William Woodward; Catherine Godfrey; Ann Wiegand; Frank Maldarelli; Sarah Palmer; John M Coffin; John W Mellors; Susan Swindells Journal: J Infect Dis Date: 2009-03-15 Impact factor: 5.226
Authors: Theresa L Whiteside; Paolo Piazza; Amanda Reiter; Joanna Stanson; Nancy C Connolly; Charles R Rinaldo; Sharon A Riddler Journal: Clin Vaccine Immunol Date: 2008-11-26
Authors: Nancy C Connolly; Theresa L Whiteside; Cara Wilson; Venkatswarlu Kondragunta; Charles R Rinaldo; Sharon A Riddler Journal: Clin Vaccine Immunol Date: 2007-10-17
Authors: Frank Maldarelli; Sarah Palmer; Martin S King; Ann Wiegand; Michael A Polis; JoAnn Mican; Joseph A Kovacs; Richard T Davey; Diane Rock-Kress; Robin Dewar; Shuying Liu; Julia A Metcalf; Catherine Rehm; Scott C Brun; George J Hanna; Dale J Kempf; John M Coffin; John W Mellors Journal: PLoS Pathog Date: 2007-04 Impact factor: 6.823
Authors: Pablo Tebas; Julie K Jadlowsky; Pamela A Shaw; Lifeng Tian; Erin Esparza; Andrea L Brennan; Sukyung Kim; Soe Yu Naing; Max W Richardson; Ashley N Vogel; Colby R Maldini; Hong Kong; Xiaojun Liu; Simon F Lacey; Anya M Bauer; Felicity Mampe; Lee P Richman; Gary Lee; Dale Ando; Bruce L Levine; David L Porter; Yangbing Zhao; Don L Siegel; Katharine J Bar; Carl H June; James L Riley Journal: J Clin Invest Date: 2021-04-01 Impact factor: 19.456
Authors: Antonio Victor Campos Coelho; Ronald Rodrigues de Moura; Anselmo Jiro Kamada; Ronaldo Celerino da Silva; Rafael Lima Guimarães; Lucas André Cavalcanti Brandão; Luiz Cláudio Arraes de Alencar; Sergio Crovella Journal: Int J Mol Sci Date: 2016-11-26 Impact factor: 5.923